Human recombinant endostatin Endostar attenuates hepatic sinusoidal endothelial cell capillarization in CCl4‑induced fibrosis in mice

You,Qi; Kong,Ling‑Jian; Li,Feng‑Dong; Wang,Hang‑Yu; Liu,Dian‑Gang; Pei,Feng‑Hua; Song,Ji‑Tao; Xu,Jun; Chen,Jing

doi:10.3892/mmr.2015.4103

Human recombinant endostatin Endostar attenuates hepatic sinusoidal endothelial cell capillarization in CCl4‑induced fibrosis in mice

Authors:
- Qi You
- Ling‑Jian Kong
- Feng‑Dong Li
- Hang‑Yu Wang
- Dian‑Gang Liu
- Feng‑Hua Pei
- Ji‑Tao Song
- Jun Xu
- Jing Chen
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150080, P.R. China, Department of Gastroenterology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150086, P.R. China, Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, P.R. China
Published online on: July 20, 2015 https://doi.org/10.3892/mmr.2015.4103
Pages: 5594-5600

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to detect the effect of the recombinant human endostatin Endostar on hepatic sinusoidal capillarization in CCl4‑induced murine models of liver fibrosis. The liver fibrosis model was induced in BALB/c mice using intraperitoneal injection of CCl4 for 6 weeks. Animals were divided into the following six treatment groups: Group 1, normal animals; group 2, CCl4‑induced liver fibrosis; group 3, CCl4+Endostar 20 mg/kg/day for 6 weeks; group 4, CCl4+Endostar 10 mg/kg/day for 6 weeks; group 5, CCl4+Endostar 20 mg/kg/day for 4 weeks; and group 6, CCl4+Endostar 10 mg/kg/day for 4 weeks. The average number of fenestrae per hepatic sinusoid was determined using transmission electron microscopy. Vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) 1 and 2 expression was detected by western blot analysis. There were significant differences in the number of fenestrae per sinusoid between the normal control and untreated model fibrotic mice (P<0.01), and between the untreated model and Endostar‑treated mice (P<0.05). Endostar treatment was associated with reduced levels of VEGFR1 and VEGFR2 in liver tissues (P<0.01), as well as with decreased hepatic sinusoidal endothelial cell capillarization in CCl4‑induced mouse models of liver fibrosis, and this effect may involve the VEGF pathway. However, further studies are required to confirm its involvement in other causes of liver fibrosis.

View Figures

View References

1	Braet F and Wisse E: Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: A review. Comp Hepatol. 1:12002. View Article : Google Scholar : PubMed/NCBI
2	Iwakiri Y and Groszmann RJ: Vascular endothelial dysfunction in cirrhosis. J Hepatol. 46:927–934. 2007. View Article : Google Scholar : PubMed/NCBI
3	Deleve LD, Wang X and Guo Y: Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence. Hepatology. 48:920–930. 2008. View Article : Google Scholar : PubMed/NCBI
4	Ling Y, Yang Y, Lu N, You QD, Wang S, Gao Y, Chen Y and Guo QL: Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun. 361:79–84. 2007. View Article : Google Scholar : PubMed/NCBI
5	Whitworth A: Endostatin: are we waiting for Godot? J Natl Cancer Inst. 98:731–733. 2006. View Article : Google Scholar : PubMed/NCBI
6	Tong Y, Zhong K, Tian H, Gao X, Xu X, Yin X and Yao W: Characterization of a monoPEG20000-Endostar. Int J Biol Macromol. 46:331–336. 2010. View Article : Google Scholar : PubMed/NCBI
7	Ni Q, Ji H, Zhao Z, Fan X and Xu C: Endostar, a modified endostatin inhibits non small cell lung cancer cell in vitro invasion through osteopontin-related mechanism. Eur J Pharmacol. 614:1–6. 2009. View Article : Google Scholar : PubMed/NCBI
8	Li XQ, Shang BY, Wang DC, Zhang SH, Wu SY and Zhen YS: Endostar, a modifed recombinant human endostatin, exhibits synergistic effects with dexamethasone on angiogenesis and hepatoma growth. Cancer Lett. 301:212–220. 2011. View Article : Google Scholar : PubMed/NCBI
9	Chen J, Liu DG, Yang G, Kong LJ, Du YJ, Wang HY, Li FD, Pei FH, Song JT, Fan YJ, et al: Endostar, a novel human recombinant endostatin, attenuates liver fibrosis in CCl4-induced mice. Exp Biol Med (Maywood). 239:998–1006. 2014. View Article : Google Scholar
10	Wang H, Zhang Y, Wang T, You H and Jia J: N-methyl-4-isoleucine cyclosporine attenuates CCl-induced liver fibrosis in rats by interacting with cyclophilin B and D. J Gastroenterol Hepatol. 26:558–567. 2011. View Article : Google Scholar : PubMed/NCBI
11	Xu H, Shi BM, Lu XF, Liang F, Jin X, Wu TH and Xu J: Vascular endothelial growth factor attenuates hepatic sinusoidal capillarization in thioacetamide-induced cirrhotic rats. World J Gastroenterol. 14:2349–2357. 2008. View Article : Google Scholar : PubMed/NCBI
12	Fernández M, Semela D, Bruix J, Colle I, Pinzani M and Bosch J: Angiogenesis in liver disease. J Hepatol. 50:604–620. 2009. View Article : Google Scholar : PubMed/NCBI
13	Coulon S, Heindryckx F, Geerts A, Van Steenkiste C, Colle I and Van Vlierberghe H: Angiogenesis in chronic liver disease and its complications. Liver Int. 31:146–162. 2011. View Article : Google Scholar
14	Thabut D and Shah V: Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: New targets for the treatment of portal hypertension? J Hepatol. 53:976–980. 2010. View Article : Google Scholar : PubMed/NCBI
15	Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J and Fernandez M: Beneficial effects of sorafenib on splanchnic, intrahepatic and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology. 49:1245–1256. 2009. View Article : Google Scholar : PubMed/NCBI
16	Majumder S, Piguet AC, Dufour JF and Chatterjee S: Study of the cellular mechanism of Sunitinib mediated inactivation of activated hepatic stellate cells and its implications in angiogenesis. Eur J Pharmacol. 705:86–95. 2013. View Article : Google Scholar : PubMed/NCBI
17	Thabut D, Routray C, Lomberk G, Shergill U, Glaser K, Huebert R, Patel L, Masyuk T, Blechacz B, Vercnocke A, et al: Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis. Hepatology. 54:573–585. 2011. View Article : Google Scholar : PubMed/NCBI
18	Olsson AK, Dimberg A, Kreuger J and Claesson-Welsh L: VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol. 7:359–371. 2006. View Article : Google Scholar : PubMed/NCBI
19	Koch S and Claesson-Welsh L: Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb Perspect Med. 2:a0065022012. View Article : Google Scholar : PubMed/NCBI
20	Koch S, Tugues S, Li X, Gualandi L and Claesson-Welsh L: Signal transduction by vascular endothelial growth factor receptors. Biochem J. 437:169–183. 2011. View Article : Google Scholar : PubMed/NCBI
21	Finley SD, Dhar M and Popel AS: Compartment model predicts VEGF secretion and investigates the effects of VEGF trap in tumor-bearing mice. Front Oncol. 3:1962013. View Article : Google Scholar : PubMed/NCBI
22	Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Hicklin DJ, Wu Y, Yanase K, Namisaki T, Yamazaki M, Tsujinoue H, Imazu H, et al: Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut. 52:1347–1354. 2003. View Article : Google Scholar : PubMed/NCBI
23	Moreau R: VEGF-induced angiogenesis drives collateral circulation in portal hypertension. J Hepatol. 43:6–8. 2005. View Article : Google Scholar : PubMed/NCBI
24	Vanheule E, Geerts AM, Van Huysse J, Schelfhout D, Praet M, Van Vlierberghe H, De Vos M and Colle I: An intravital microscopic study of the hepatic microcirculation in cirrhotic mice models: Relationship between fibrosis and angiogenesis. Int J Exp Pathol. 89:419–432. 2008. View Article : Google Scholar
25	Ankoma-Sey V, Matli M, Chang KB, Lalazar A, Donner DB, Wong L, Warren RS and Friedman SL: Coordinated induction of VEGF receptors in mesenchymal cell types during rat hepatic wound healing. Oncogene. 17:115–121. 1998. View Article : Google Scholar : PubMed/NCBI
26	Coulon S, Heindryckx F, Geerts A, Van Steenkiste C, Colle I and Van Vlierberghe H: Angiogenesis in chronic liver disease and its complications. Liver Int. 31:146–162. 2011. View Article : Google Scholar
27	Friedman SL: Preface. Hepatic fibrosis: Pathogenesis, diagnosis and emerging therapies. Clin Liver Dis. 12:xiii–xiv. 2008. View Article : Google Scholar